Abstract
BackgroundUrethral obstruction (UO) is a common complication of feline idiopathic cystitis (FIC). Robust treatment recommendations to prevent its recurrence are scarce.ObjectivesTo evaluate meloxicam treatment for prevention of clinical recrudescence in male cats with obstructive FIC.AnimalsFifty‐one client‐owned cats.MethodsProspective, randomized clinical trial. Every male cat with FIC‐associated UO was deemed eligible for the study and was recruited during hospitalization. After discharge, cats were treated with phenoxybenzamine and alprazolam for 2 weeks, with (24 cats) or without (27 cats) low‐dose meloxicam (0.025 mg/kg/day PO) and monitored for 6 months.ResultsCumulative number (%) of cats with recurrent UO at 10 days, 1‐, 2‐, and 6‐months after discharge was 1 (2%), 2 (4%), 4 (8%), and 8 (16%), respectively. Overall, 12 (24%) cats experienced signs of recurrent FIC within 6 months, with (8 cats) or without (4 cats) concurrent UO. No difference in the cumulative incidence of UO within 6 months was detected with addition of meloxicam (odds ratio [95% confidence interval], 0.63 [0.13‐2.97]; P = .70). All cats were alive at 6 months.Conclusions and Clinical ImportanceNo clinical benefit was detected with the addition of low‐dose meloxicam to phenoxybenzamine and alprazolam treatment for 2 weeks after discharge. Nevertheless, this study was underpowered to identify potential differences, and its findings must be corroborated in larger studies.
Highlights
Feline idiopathic cystitis (FIC) accounts for up to 55% to 65% of lower urinary tract (LUT) diseases in cats.[1,2] A plethora of risk factors and purported physiological and behavioral alterations have been associated with feline idiopathic cystitis (FIC), but robust evidence regarding its pathogenesis is lacking, and the underlying causes of this noninfectious, inflammatory disease remain poorly elucidated.[3]
Owing to the consequences of recurrence, and lack of evidencebased, effective treatment protocols, we aimed to evaluate the efficacy of a 2-week-long, low-dose oral meloxicam treatment in reducing recurrence of urethral obstruction in male cats with obstructive FIC
Prospective clinical trial, cumulative recurrence of urethral obstruction (rUO) rates over a 6-month follow-up period were low and no differences in recurrence rates at multiple time points were detected with the addition of low-dose meloxicam
Summary
Feline idiopathic cystitis (FIC) accounts for up to 55% to 65% of lower urinary tract (LUT) diseases in cats.[1,2] A plethora of risk factors and purported physiological and behavioral alterations have been associated with FIC, but robust evidence regarding its pathogenesis is lacking, and the underlying causes of this noninfectious, inflammatory disease remain poorly elucidated.[3]. A plethora of risk factors and purported physiological and behavioral alterations have been associated with FIC, but robust evidence regarding its pathogenesis is lacking, and the underlying causes of this noninfectious, inflammatory disease remain poorly elucidated.[3]. Objectives: To evaluate meloxicam treatment for prevention of clinical recrudescence in male cats with obstructive FIC. Cats were treated with phenoxybenzamine and alprazolam for 2 weeks, with (24 cats) or without (27 cats) low-dose meloxicam (0.025 mg/kg/day PO) and monitored for 6 months. Results: Cumulative number (%) of cats with recurrent UO at 10 days, 1-, 2-, and 6-months after discharge was 1 (2%), 2 (4%), 4 (8%), and 8 (16%), respectively. Conclusions and Clinical Importance: No clinical benefit was detected with the addition of low-dose meloxicam to phenoxybenzamine and alprazolam treatment for 2 weeks after discharge. This study was underpowered to identify potential differences, and its findings must be corroborated in larger studies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
